Zdrowie i gospodarka · 01/10/2013

FDA Publishes Draft Guidance on Refuse-to-Receive Standards for Abbreviated New Drug Application Submissions

The US Food and Drug Administration (FDA) has released a draft guidance document to help pharmaceutical companies prepare their submissions for abbreviated new drug applications (ANDAs) and related supplements, outlining the standards for submissions that may be rejected by the FDA